Trial Site Detail

 

Drug:
CB-839
Trial:
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Conditions: Solid Tumors
Trial Status:
Active, not recruiting

 

Robert Lurie Comp. Cancer Center Northwestern University Hospital

675 North St. Clair     
Chicago , IL 60611
USA

 

Principal Investigator:
Contact:
Activation Status of this Site:
Closed
Notes about this Site:
Robert Lurie Comp. Cancer Center Northwestern University Hospital Website:
http://www.cancer.northwestern.edu/public/why_northwestern/clinical_trials/index.cfm

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.